This open-label 24-week extension study evaluated the safety, clinical and biological activity of C2L 30mg in acromegalic patients. Mean efficacy on IGF-1 was identical, throughout Study 302, to what it was after 84 days (12 weeks) of treatment in the first part of Study 301 with either C2L or SLAR. This suggests that switching from SLAR every four weeks to C2L every six weeks does not induce a decrease in IGF-1 response, even after 36 additional weeks follow-up.

Efficacy on GH was also maintained throughout Study 302, again supporting that switching from SLAR every four weeks to C2L every six weeks at the same dose yields the same efficacy on GH control in acromegalics over an extended period of time. The number of patients with normalized IGF-1 or GH levels was identical or slightly higher (though not significantly) after treatment with C2L as compared to SLAR.

Overall, the top-line analysis of the results supports the ability of C2L 30mg given every six weeks to replace SLAR given every four weeks at the same dose, with mean efficacy and safety maintained over an additional six months treatment. The company expects regulatory filings to be initiated before the end of 2008.

Philippe Calais, president and CEO of Ambrilia, said: "These new data further validate C2L's potential to be a safe, effective and cost-effective therapy, well positioned to capture a sizeable portion of the $1 billion-plus SLAR market. Again, we are progressing well toward our year-end divestment goal for C2L which could alleviate the company's financial overhang by bringing non-dilutive funding."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Ambrilia Biopharma Inc. (TSX: AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, Hepatitis C inhibitors and anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

For more information, please visit the Company's web site: www.ambrilia.com

Contacts:
Ambrilia Biopharma Inc.
Julie M. Thibodeau, B.Sc., MBA
Director, Communications
514-751-2003 ext 235
jthibodeau@ambrilia.com or ir@ambrilia.com
www.ambrilia.com

SOURCE: Ambrilia Biopharma Inc.

mailto:jthibodeau@ambrilia.com
mailto:ir@ambrilia.com
http://www.ambrilia.com

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX: AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, Hepatitis C inhibitors and anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

For more information, please visit the Company's web site: www.ambrilia.com Contacts: Ambrilia Biopharma Inc. Julie M. Thibodeau, B.Sc., MBA Director, Communications 514-751-2003, ext. 235 jthibodeau@ambrilia.com or ir@ambrilia.com www.ambrilia.com

SOURCE: Ambrilia Biopharma Inc.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, Hepatitis C inhibitors and anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

For more information, please visit the Company's web site: www.ambrilia.com

SOURCE: Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.
Julie M. Thibodeau, B.Sc., MBA
Director, Communications
514-751-2003, ext. 235
jthibodeau@ambrilia.com or ir@ambrilia.com
www.ambrilia.com